SlideShare a Scribd company logo
UNIVERSITY OF COLORADO | COLORADO STATE UNIVERSITY | UNIVERSITY OF NORTHERN COLORADO
Reducing Time to
Bacterial Identification
in Blood Stream Infections
Veronica Ann Broslawik, MLS (ASCP)CM
MPH Candidate | Epidemiology
Colorado School of Public Health Forum
December 5, 2014
with Drs. Nancy Madinger and Bruce McCollister
University of Colorado Hospital
Clinical Microbiology Laboratory
Introduction
• Blood Stream Infections (BSIs)
– Frequently result in critical illness
– Associated with high morbidity and mortality rates
• Antibiotic Administration
– Adequate and appropriate
– Timely
Introduction
• Matrix-Assisted Laser Desorption Ionization,
Time of Flight Mass Spectrometry (MALDI-TOF MS)
– Revolutionary bacteria identification
– Easy, fast, and low-cost method for identification
– Compared to phenotypic identification techniques
Study Objective
• This study aimed to examine the impact of
implementation of a MALDI-TOF MS
instrument on time to identification of
bacteria causing blood stream infections in
a clinical microbiology laboratory.
Methods
• Retrospective, quasi-experimental, before/after study
• Culture Inclusion Criteria
• Gram negative rods in the Enterobacteriaciae group
(examples: E. coli or Salmonella species)
• Received in the lab from June 2013 to August 2014
• From inpatients at University of Colorado Hospital
• First positive culture
• Not a mixed infection
• Antibiotic sensitivity testing completed
Results
0
24
48
72
96
120
HourstoIdentification
Identifications Before Implementation of MALDI-TOF
BEFORE MALDI Average Time to Identification Before MALDI
n mean 95% CI
153 38.05 35.36-40.73
Results
0
24
48
72
96
120
HourstoIdentification
Identifications After Implementation of MALDI-TOF
AFTER MALDI Average Time to Identification After MALDI
n mean 95% CI
104 26.68 24.61-28.76
Results
0
24
48
72
96
120
HourstoIdentification
Identifications Before and After Implementation of MALDI-TOF MS
Before MALDI After MALDI
Mean Time to Identification Before MALDI = 38.04 hours Mean Time to Identification After MALDI = 26.68 hours
Results
BloodCulture
Drawn
BeforeMALDIAfterMALDI
0 12 24 36 48 60 72
Hours After Culture Positivity
CulturePositive
TimetoBacterial
Identification
TimetoAntibiotic
SusceptibilityResults
38.04
26.68
Results
BloodCulture
Drawn
BeforeMALDIAfterMALDI
0 12 24 36 48 60 72
Hours After Culture Positivity
CulturePositive
38.04
Time to Identification
Mean (hours) 95% CI (hours)
Before MALDI 38.04 35.56 - 40.73
After MALDI 26.68 24.61 - 28.76
26.68
Results
BloodCulture
Drawn
BeforeMALDIAfterMALDI
0 12 24 36 48 60 72
Hours After Culture Positivity
CulturePositive
Time to Identification
MALDI-TOF identification takes 7-15 hours less
time compared to phenotypic identification.
( α = 0.05 pvalue <0.001).
38.04
26.68
Results
The implementation of the MALDI-TOF MS
brought significant decreases in time to
identification of gram negative bacteria
at the University of Colorado Hospital.
Discussion
• MALDI-TOF improves laboratory process
identification of bacteria causing BSIs over
phenotypic identification techniques
• 750,000 blood stream infections/year in the US
- 25% gram negative bacteria  187,500 people
• MALDI-TOF MS is highly sensitive and specific
• Every hour in delay to appropriate antibiotic
treatment decreases patient survival by 7.6%
Public Health Context
BloodCulture
Drawn
BeforeMALDIAfterMALDI
0 12 24 36 48 60 72
Hours After Culture Positivity
CulturePositive
TimetoBacterial
Identification
TimetoAntibiotic
SusceptibilityResults
Public Health Context
BloodCulture
Drawn
BeforeMALDIAfterMALDI
0 12 24 36 48 60 72
Hours After Culture Positivity
CulturePositive Time to
Identification
Time to
Antibiotic
Susceptibility
Results
Acknowledgments
• Nancy Madinger, MD and Bruce McCollister, MD Medical
Directors, University of Colorado Hospital Clinical Microbiology Laboratory
• Deborah Havens, MLS(ASCP)
Chief Medical Technologist, University of Colorado Hospital Clinical Microbiology Laboratory
• University of Colorado Hospital Clinical Microbiology
Laboratory Staff
– Especially Mehdi Bandali and Elizabeth Matthys
• Colorado School of Public Health Capstone Classmates
and Instructors
Questions?

More Related Content

What's hot

Thornton NAAT
Thornton NAATThornton NAAT
Thornton NAAT
DSHS
 
Establishing validity, reproducibility, and utility of highly scalable geneti...
Establishing validity, reproducibility, and utility of highly scalable geneti...Establishing validity, reproducibility, and utility of highly scalable geneti...
Establishing validity, reproducibility, and utility of highly scalable geneti...
Human Variome Project
 
Dried blood spot HIV testing
Dried blood spot HIV testingDried blood spot HIV testing
Dried blood spot HIV testing
Australian Federation of AIDS Organisations
 
Mihiret wachamo tesema 22525
Mihiret wachamo tesema 22525Mihiret wachamo tesema 22525
Mihiret wachamo tesema 22525
NawarRizk1
 
NAAT IN BLOOD BANKING
NAAT IN BLOOD BANKINGNAAT IN BLOOD BANKING
NAAT IN BLOOD BANKING
Narmada Tiwari
 
PH525.6x: Case study: Variant Discovery and Genotyping Certificate
PH525.6x: Case study: Variant Discovery and Genotyping CertificatePH525.6x: Case study: Variant Discovery and Genotyping Certificate
PH525.6x: Case study: Variant Discovery and Genotyping Certificate
VICTOR MAESTRE RAMIREZ
 
Accomplishments V Shyamala
Accomplishments V ShyamalaAccomplishments V Shyamala
Accomplishments V Shyamala
V Shyamala
 
Targos_Company_Brochure_lowres
Targos_Company_Brochure_lowresTargos_Company_Brochure_lowres
Targos_Company_Brochure_lowres
Targos Inc, San Bruno, California
 
Clinical Validation of Copy Number Variants Using the AMP Guidelines
Clinical Validation of Copy Number Variants Using the AMP GuidelinesClinical Validation of Copy Number Variants Using the AMP Guidelines
Clinical Validation of Copy Number Variants Using the AMP Guidelines
Golden Helix
 

What's hot (9)

Thornton NAAT
Thornton NAATThornton NAAT
Thornton NAAT
 
Establishing validity, reproducibility, and utility of highly scalable geneti...
Establishing validity, reproducibility, and utility of highly scalable geneti...Establishing validity, reproducibility, and utility of highly scalable geneti...
Establishing validity, reproducibility, and utility of highly scalable geneti...
 
Dried blood spot HIV testing
Dried blood spot HIV testingDried blood spot HIV testing
Dried blood spot HIV testing
 
Mihiret wachamo tesema 22525
Mihiret wachamo tesema 22525Mihiret wachamo tesema 22525
Mihiret wachamo tesema 22525
 
NAAT IN BLOOD BANKING
NAAT IN BLOOD BANKINGNAAT IN BLOOD BANKING
NAAT IN BLOOD BANKING
 
PH525.6x: Case study: Variant Discovery and Genotyping Certificate
PH525.6x: Case study: Variant Discovery and Genotyping CertificatePH525.6x: Case study: Variant Discovery and Genotyping Certificate
PH525.6x: Case study: Variant Discovery and Genotyping Certificate
 
Accomplishments V Shyamala
Accomplishments V ShyamalaAccomplishments V Shyamala
Accomplishments V Shyamala
 
Targos_Company_Brochure_lowres
Targos_Company_Brochure_lowresTargos_Company_Brochure_lowres
Targos_Company_Brochure_lowres
 
Clinical Validation of Copy Number Variants Using the AMP Guidelines
Clinical Validation of Copy Number Variants Using the AMP GuidelinesClinical Validation of Copy Number Variants Using the AMP Guidelines
Clinical Validation of Copy Number Variants Using the AMP Guidelines
 

Viewers also liked

Sample Presentation1
Sample Presentation1Sample Presentation1
Sample Presentation1
Wurdart
 
P R E S E A U R O R A
P R E S E  A U R O R AP R E S E  A U R O R A
P R E S E A U R O R A
Aurora Sanchez
 
Tecnologías de punta 8c
Tecnologías de punta 8cTecnologías de punta 8c
Tecnologías de punta 8c
javieracoronado1276327
 
Background
BackgroundBackground
Background
Myrah Burbos
 
Bilda valentín (zenaida)
Bilda valentín (zenaida)Bilda valentín (zenaida)
Bilda valentín (zenaida)
Paula Marcelo Martínez
 
Drew Will Design & Illustration samples
Drew Will Design & Illustration samplesDrew Will Design & Illustration samples
Drew Will Design & Illustration samples
Drew Will
 
Cloud transformation enabling through tsg service lifecycle tool by helmuth z...
Cloud transformation enabling through tsg service lifecycle tool by helmuth z...Cloud transformation enabling through tsg service lifecycle tool by helmuth z...
Cloud transformation enabling through tsg service lifecycle tool by helmuth z...
Khazret Sapenov
 
Assignment no 2- PPM-IT
Assignment no 2- PPM-ITAssignment no 2- PPM-IT
Assignment no 2- PPM-IT
ManasiParulekar
 
Value, application, synthesis
Value, application, synthesisValue, application, synthesis
Value, application, synthesis
Neil Clavin
 
Proyecto de innovación Catalina Abreu
Proyecto de innovación Catalina AbreuProyecto de innovación Catalina Abreu
Proyecto de innovación Catalina Abreu
Paula Marcelo Martínez
 
Bitnami & Oracle Cloud Platform
Bitnami & Oracle Cloud PlatformBitnami & Oracle Cloud Platform
Bitnami & Oracle Cloud Platform
Jean-Philippe PINTE
 
Rumusan spm
Rumusan spmRumusan spm
Rumusan spm
AnIf AmaLina Achik
 

Viewers also liked (13)

Sample Presentation1
Sample Presentation1Sample Presentation1
Sample Presentation1
 
P R E S E A U R O R A
P R E S E  A U R O R AP R E S E  A U R O R A
P R E S E A U R O R A
 
Tecnologías de punta 8c
Tecnologías de punta 8cTecnologías de punta 8c
Tecnologías de punta 8c
 
Kirola
KirolaKirola
Kirola
 
Background
BackgroundBackground
Background
 
Bilda valentín (zenaida)
Bilda valentín (zenaida)Bilda valentín (zenaida)
Bilda valentín (zenaida)
 
Drew Will Design & Illustration samples
Drew Will Design & Illustration samplesDrew Will Design & Illustration samples
Drew Will Design & Illustration samples
 
Cloud transformation enabling through tsg service lifecycle tool by helmuth z...
Cloud transformation enabling through tsg service lifecycle tool by helmuth z...Cloud transformation enabling through tsg service lifecycle tool by helmuth z...
Cloud transformation enabling through tsg service lifecycle tool by helmuth z...
 
Assignment no 2- PPM-IT
Assignment no 2- PPM-ITAssignment no 2- PPM-IT
Assignment no 2- PPM-IT
 
Value, application, synthesis
Value, application, synthesisValue, application, synthesis
Value, application, synthesis
 
Proyecto de innovación Catalina Abreu
Proyecto de innovación Catalina AbreuProyecto de innovación Catalina Abreu
Proyecto de innovación Catalina Abreu
 
Bitnami & Oracle Cloud Platform
Bitnami & Oracle Cloud PlatformBitnami & Oracle Cloud Platform
Bitnami & Oracle Cloud Platform
 
Rumusan spm
Rumusan spmRumusan spm
Rumusan spm
 

Similar to Final Presentation

The MALDI-TOF application in diagnostic of microbial agents of contagious dis...
The MALDI-TOF application in diagnostic of microbial agents of contagious dis...The MALDI-TOF application in diagnostic of microbial agents of contagious dis...
The MALDI-TOF application in diagnostic of microbial agents of contagious dis...
improvemed
 
The MALDI-TOF application in diagnostic of microbial agents of contagious di...
 The MALDI-TOF application in diagnostic of microbial agents of contagious di... The MALDI-TOF application in diagnostic of microbial agents of contagious di...
The MALDI-TOF application in diagnostic of microbial agents of contagious di...
improvemed
 
PPT MOLECULAR DIG gram +ve bacteria.....
PPT MOLECULAR DIG gram +ve bacteria.....PPT MOLECULAR DIG gram +ve bacteria.....
PPT MOLECULAR DIG gram +ve bacteria.....
Dr. Ajit Surya Singh
 
Journal Club (Systematic Review & Meta Analysis)
Journal Club (Systematic Review & Meta Analysis) Journal Club (Systematic Review & Meta Analysis)
Journal Club (Systematic Review & Meta Analysis)
Abdullatif Al-Rashed
 
Artificial Intelligence In Microbiology by Dr. Prince C P
Artificial Intelligence In Microbiology by Dr. Prince C PArtificial Intelligence In Microbiology by Dr. Prince C P
Artificial Intelligence In Microbiology by Dr. Prince C P
DR.PRINCE C P
 
Use of MALDI-TOF in the diagnosis of infectious diseases
Use of MALDI-TOF in the diagnosis of infectious diseasesUse of MALDI-TOF in the diagnosis of infectious diseases
Use of MALDI-TOF in the diagnosis of infectious diseases
improvemed
 
Development of quality control assays for cell-based medicinal products (ISCT...
Development of quality control assays for cell-based medicinal products (ISCT...Development of quality control assays for cell-based medicinal products (ISCT...
Development of quality control assays for cell-based medicinal products (ISCT...
Quality Assistance s.a.
 
First Coast Final
First Coast FinalFirst Coast Final
First Coast Final
Aurora Muhuza
 
691632.ppt
691632.ppt691632.ppt
691632.ppt
Shinee13
 
Invest to End TB. Save Lives
Invest to End TB. Save LivesInvest to End TB. Save Lives
Invest to End TB. Save Lives
Stop TB Italia Onlus
 
LaboratorydiagnosisofTB.pptx
LaboratorydiagnosisofTB.pptxLaboratorydiagnosisofTB.pptx
LaboratorydiagnosisofTB.pptx
Kanishka478113
 
Laboratory diagnosis of Tuberculosis
Laboratory diagnosis of TuberculosisLaboratory diagnosis of Tuberculosis
Laboratory diagnosis of Tuberculosis
Dr Dhanji Rajani
 
Diagnosis & management of tb in RNTCP
Diagnosis & management of tb in RNTCPDiagnosis & management of tb in RNTCP
Diagnosis & management of tb in RNTCP
navinthakkar
 
Automatic Detection and Classification of Malarial Parasite
Automatic Detection and Classification of Malarial ParasiteAutomatic Detection and Classification of Malarial Parasite
Automatic Detection and Classification of Malarial Parasite
CSCJournals
 
Microbicides for hiv prevention
Microbicides for hiv preventionMicrobicides for hiv prevention
Microbicides for hiv prevention
Setegn Eshetie
 
PCR Presentation v7
PCR Presentation v7PCR Presentation v7
PCR Presentation v7
Karen Erenberg, BA MLS
 
NEWER TECHNOLOGIES DIAGNOSTIC MICROBIOLOGY
NEWER TECHNOLOGIES DIAGNOSTIC MICROBIOLOGYNEWER TECHNOLOGIES DIAGNOSTIC MICROBIOLOGY
NEWER TECHNOLOGIES DIAGNOSTIC MICROBIOLOGY
Society for Microbiology and Infection care
 
Chlamydial Guidelines Belarus
Chlamydial Guidelines BelarusChlamydial Guidelines Belarus
Chlamydial Guidelines Belarus
Игорь Шадеркин
 
Advantages and Limitations of Sequencing for Identification of Mycob.pdf
Advantages and Limitations of Sequencing for Identification of Mycob.pdfAdvantages and Limitations of Sequencing for Identification of Mycob.pdf
Advantages and Limitations of Sequencing for Identification of Mycob.pdf
annucommunication1
 
Laboratory Assays Cross-sectional Incidence Testing, Blood Spots, and HIV Vir...
Laboratory AssaysCross-sectional Incidence Testing, Blood Spots, and HIV Vir...Laboratory AssaysCross-sectional Incidence Testing, Blood Spots, and HIV Vir...
Laboratory Assays Cross-sectional Incidence Testing, Blood Spots, and HIV Vir...
HopkinsCFAR
 

Similar to Final Presentation (20)

The MALDI-TOF application in diagnostic of microbial agents of contagious dis...
The MALDI-TOF application in diagnostic of microbial agents of contagious dis...The MALDI-TOF application in diagnostic of microbial agents of contagious dis...
The MALDI-TOF application in diagnostic of microbial agents of contagious dis...
 
The MALDI-TOF application in diagnostic of microbial agents of contagious di...
 The MALDI-TOF application in diagnostic of microbial agents of contagious di... The MALDI-TOF application in diagnostic of microbial agents of contagious di...
The MALDI-TOF application in diagnostic of microbial agents of contagious di...
 
PPT MOLECULAR DIG gram +ve bacteria.....
PPT MOLECULAR DIG gram +ve bacteria.....PPT MOLECULAR DIG gram +ve bacteria.....
PPT MOLECULAR DIG gram +ve bacteria.....
 
Journal Club (Systematic Review & Meta Analysis)
Journal Club (Systematic Review & Meta Analysis) Journal Club (Systematic Review & Meta Analysis)
Journal Club (Systematic Review & Meta Analysis)
 
Artificial Intelligence In Microbiology by Dr. Prince C P
Artificial Intelligence In Microbiology by Dr. Prince C PArtificial Intelligence In Microbiology by Dr. Prince C P
Artificial Intelligence In Microbiology by Dr. Prince C P
 
Use of MALDI-TOF in the diagnosis of infectious diseases
Use of MALDI-TOF in the diagnosis of infectious diseasesUse of MALDI-TOF in the diagnosis of infectious diseases
Use of MALDI-TOF in the diagnosis of infectious diseases
 
Development of quality control assays for cell-based medicinal products (ISCT...
Development of quality control assays for cell-based medicinal products (ISCT...Development of quality control assays for cell-based medicinal products (ISCT...
Development of quality control assays for cell-based medicinal products (ISCT...
 
First Coast Final
First Coast FinalFirst Coast Final
First Coast Final
 
691632.ppt
691632.ppt691632.ppt
691632.ppt
 
Invest to End TB. Save Lives
Invest to End TB. Save LivesInvest to End TB. Save Lives
Invest to End TB. Save Lives
 
LaboratorydiagnosisofTB.pptx
LaboratorydiagnosisofTB.pptxLaboratorydiagnosisofTB.pptx
LaboratorydiagnosisofTB.pptx
 
Laboratory diagnosis of Tuberculosis
Laboratory diagnosis of TuberculosisLaboratory diagnosis of Tuberculosis
Laboratory diagnosis of Tuberculosis
 
Diagnosis & management of tb in RNTCP
Diagnosis & management of tb in RNTCPDiagnosis & management of tb in RNTCP
Diagnosis & management of tb in RNTCP
 
Automatic Detection and Classification of Malarial Parasite
Automatic Detection and Classification of Malarial ParasiteAutomatic Detection and Classification of Malarial Parasite
Automatic Detection and Classification of Malarial Parasite
 
Microbicides for hiv prevention
Microbicides for hiv preventionMicrobicides for hiv prevention
Microbicides for hiv prevention
 
PCR Presentation v7
PCR Presentation v7PCR Presentation v7
PCR Presentation v7
 
NEWER TECHNOLOGIES DIAGNOSTIC MICROBIOLOGY
NEWER TECHNOLOGIES DIAGNOSTIC MICROBIOLOGYNEWER TECHNOLOGIES DIAGNOSTIC MICROBIOLOGY
NEWER TECHNOLOGIES DIAGNOSTIC MICROBIOLOGY
 
Chlamydial Guidelines Belarus
Chlamydial Guidelines BelarusChlamydial Guidelines Belarus
Chlamydial Guidelines Belarus
 
Advantages and Limitations of Sequencing for Identification of Mycob.pdf
Advantages and Limitations of Sequencing for Identification of Mycob.pdfAdvantages and Limitations of Sequencing for Identification of Mycob.pdf
Advantages and Limitations of Sequencing for Identification of Mycob.pdf
 
Laboratory Assays Cross-sectional Incidence Testing, Blood Spots, and HIV Vir...
Laboratory AssaysCross-sectional Incidence Testing, Blood Spots, and HIV Vir...Laboratory AssaysCross-sectional Incidence Testing, Blood Spots, and HIV Vir...
Laboratory Assays Cross-sectional Incidence Testing, Blood Spots, and HIV Vir...
 

Final Presentation

  • 1. UNIVERSITY OF COLORADO | COLORADO STATE UNIVERSITY | UNIVERSITY OF NORTHERN COLORADO Reducing Time to Bacterial Identification in Blood Stream Infections Veronica Ann Broslawik, MLS (ASCP)CM MPH Candidate | Epidemiology Colorado School of Public Health Forum December 5, 2014 with Drs. Nancy Madinger and Bruce McCollister University of Colorado Hospital Clinical Microbiology Laboratory
  • 2. Introduction • Blood Stream Infections (BSIs) – Frequently result in critical illness – Associated with high morbidity and mortality rates • Antibiotic Administration – Adequate and appropriate – Timely
  • 3. Introduction • Matrix-Assisted Laser Desorption Ionization, Time of Flight Mass Spectrometry (MALDI-TOF MS) – Revolutionary bacteria identification – Easy, fast, and low-cost method for identification – Compared to phenotypic identification techniques
  • 4. Study Objective • This study aimed to examine the impact of implementation of a MALDI-TOF MS instrument on time to identification of bacteria causing blood stream infections in a clinical microbiology laboratory.
  • 5. Methods • Retrospective, quasi-experimental, before/after study • Culture Inclusion Criteria • Gram negative rods in the Enterobacteriaciae group (examples: E. coli or Salmonella species) • Received in the lab from June 2013 to August 2014 • From inpatients at University of Colorado Hospital • First positive culture • Not a mixed infection • Antibiotic sensitivity testing completed
  • 6. Results 0 24 48 72 96 120 HourstoIdentification Identifications Before Implementation of MALDI-TOF BEFORE MALDI Average Time to Identification Before MALDI n mean 95% CI 153 38.05 35.36-40.73
  • 7. Results 0 24 48 72 96 120 HourstoIdentification Identifications After Implementation of MALDI-TOF AFTER MALDI Average Time to Identification After MALDI n mean 95% CI 104 26.68 24.61-28.76
  • 8. Results 0 24 48 72 96 120 HourstoIdentification Identifications Before and After Implementation of MALDI-TOF MS Before MALDI After MALDI Mean Time to Identification Before MALDI = 38.04 hours Mean Time to Identification After MALDI = 26.68 hours
  • 9. Results BloodCulture Drawn BeforeMALDIAfterMALDI 0 12 24 36 48 60 72 Hours After Culture Positivity CulturePositive TimetoBacterial Identification TimetoAntibiotic SusceptibilityResults 38.04 26.68
  • 10. Results BloodCulture Drawn BeforeMALDIAfterMALDI 0 12 24 36 48 60 72 Hours After Culture Positivity CulturePositive 38.04 Time to Identification Mean (hours) 95% CI (hours) Before MALDI 38.04 35.56 - 40.73 After MALDI 26.68 24.61 - 28.76 26.68
  • 11. Results BloodCulture Drawn BeforeMALDIAfterMALDI 0 12 24 36 48 60 72 Hours After Culture Positivity CulturePositive Time to Identification MALDI-TOF identification takes 7-15 hours less time compared to phenotypic identification. ( α = 0.05 pvalue <0.001). 38.04 26.68
  • 12. Results The implementation of the MALDI-TOF MS brought significant decreases in time to identification of gram negative bacteria at the University of Colorado Hospital.
  • 13. Discussion • MALDI-TOF improves laboratory process identification of bacteria causing BSIs over phenotypic identification techniques • 750,000 blood stream infections/year in the US - 25% gram negative bacteria  187,500 people • MALDI-TOF MS is highly sensitive and specific • Every hour in delay to appropriate antibiotic treatment decreases patient survival by 7.6%
  • 14. Public Health Context BloodCulture Drawn BeforeMALDIAfterMALDI 0 12 24 36 48 60 72 Hours After Culture Positivity CulturePositive TimetoBacterial Identification TimetoAntibiotic SusceptibilityResults
  • 15. Public Health Context BloodCulture Drawn BeforeMALDIAfterMALDI 0 12 24 36 48 60 72 Hours After Culture Positivity CulturePositive Time to Identification Time to Antibiotic Susceptibility Results
  • 16. Acknowledgments • Nancy Madinger, MD and Bruce McCollister, MD Medical Directors, University of Colorado Hospital Clinical Microbiology Laboratory • Deborah Havens, MLS(ASCP) Chief Medical Technologist, University of Colorado Hospital Clinical Microbiology Laboratory • University of Colorado Hospital Clinical Microbiology Laboratory Staff – Especially Mehdi Bandali and Elizabeth Matthys • Colorado School of Public Health Capstone Classmates and Instructors